Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Tanguy Pacé-Loscos"'
Autor:
Jean-Michel Hannoun-Levi, Marie-Eve Chand-Fouche, Tanguy Pace-Loscos, Mathieu Gautier, Jocelyn Gal, Renaud Schiappa, Nina Pujol
Publikováno v:
Clinical and Translational Radiation Oncology, Vol 37, Iss , Pp 64-70 (2022)
Purpose: To report the results of the Single Fraction Early Prostate Irradiation (SiFEPI) phase 2 prospective trial. Materials/Methods: The SiFEPI trial (NCT02104362) evaluated a single fraction of high-dose rate brachytherapy (HDB) for low- (LR) and
Externí odkaz:
https://doaj.org/article/ba481b83c50843eb84967432af6eff73
Autor:
Tanguy Pace-Loscos, Jocelyn Gal, Sara Contu, Renaud Schiappa, Emmanuel Chamorey, Dorian Culié
Publikováno v:
BMC Bioinformatics, Vol 25, Iss 1, Pp 1-11 (2024)
Abstract Background In the realm of biomedical research, the growing volume, diversity and quantity of data has escalated the demand for statistical analysis as it is indispensable for synthesizing, interpreting, and publishing data. Hence the need f
Externí odkaz:
https://doaj.org/article/139db4ae4f754569aaa79cea74486211
Autor:
Jean-Pierre Gerard, Nicolas N. Barbet, Tanguy Pacé-Loscos, Nicolas Magné, Jessica Serrand, Laurent Mineur, Melanie Deberne, Thomas Zilli, Amandeep Singh Dhadda, Arthur Sun Myint
Publikováno v:
Journal of Clinical Oncology. 40:3512-3512
3512 Background: The OPERA trial was testing the hypothesis that Contact x-ray brachytherapy (CXB) 50 kV boost will increase the rectal preservation rate in early T2-T3ab rectal adenocarcinoma. We present the 3 years clinical results. Methods: Inclus
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::199015f9e29bfb9c6420a04498b91279
https://doi.org/10.1200/jco.2022.40.16_suppl.3512
https://doi.org/10.1200/jco.2022.40.16_suppl.3512
Autor:
Jean-Marc Ferrero, Hakim Mahammedi, Gwenaelle Gravis, Guilhem Roubaud, Philippe Beuzeboc, Remi Largillier, Delphine Borchiellini, Claude Linassier, Nathalie Ebran, Tanguy Pace-Loscos, Marie-Christine Etienne-Grimaldi, Renaud Schiappa, Jocelyn Gal, Gérard Milano
Publikováno v:
Pharmaceutics, Vol 15, Iss 2, p 651 (2023)
Abiraterone acetate (AA) is the first-in-class of drugs belonging to the second-generation of agents inhibiting androgen neosynthesis in advanced prostate cancer. A cumulative experience attests that germinal gene polymorphisms may play a role in the
Externí odkaz:
https://doaj.org/article/c04920b18f914032b1945806680881d4